Clinical / R&D
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Research & Development
Opiant could get $4.6m to accelerate development of nasal nalmefene for treatment of opioid overdose.
The Medicines Company's inclisirin CV trial is 100-fold cheaper with digitized records, while Lilly is still hunting for a good HBA1C dataset, and Merck worries about "idiosyncratic" data.
The European Medicines Agency is seeking feedback on a new Q&A it has prepared on the use of data monitoring committees by sponsors.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.